225 related articles for article (PubMed ID: 22144565)
1. Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.
Bordia T; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2012 Mar; 340(3):612-9. PubMed ID: 22144565
[TBL] [Abstract][Full Text] [Related]
2. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.
Bordia T; Zhang D; Perez XA; Quik M
Exp Neurol; 2016 Dec; 286():32-39. PubMed ID: 27658674
[TBL] [Abstract][Full Text] [Related]
3. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
4. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.
Quik M; Zhang D; Perez XA; Bordia T
Pharmacol Ther; 2014 Oct; 144(1):50-9. PubMed ID: 24836728
[TBL] [Abstract][Full Text] [Related]
5. α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
Quik M; Campos C; Bordia T; Strachan JP; Zhang J; McIntosh JM; Letchworth S; Jordan K
Neuropharmacology; 2013 Aug; 71():191-203. PubMed ID: 23583932
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats.
Dhingra D; Goswami S; Gahalain N
Nutr Neurosci; 2018 Nov; 21(9):667-675. PubMed ID: 28641484
[TBL] [Abstract][Full Text] [Related]
7. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.
Naidu PS; Singh A; Kulkarni SK
Br J Pharmacol; 2002 May; 136(2):193-200. PubMed ID: 12010767
[TBL] [Abstract][Full Text] [Related]
8. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate.
Egan MF; Ferguson JN; Hyde TM
Brain Res Bull; 1995; 38(4):355-63. PubMed ID: 8535858
[TBL] [Abstract][Full Text] [Related]
10. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia.
Naidu PS; Singh A; Kulkarni SK
Neuropharmacology; 2003 Jun; 44(8):1100-6. PubMed ID: 12763102
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.
Egan MF; Hurd Y; Ferguson J; Bachus SE; Hamid EH; Hyde TM
Psychopharmacology (Berl); 1996 Oct; 127(4):337-45. PubMed ID: 8923569
[TBL] [Abstract][Full Text] [Related]
12. Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia.
Röpke J; Ferreira-Vieira TH; Iglesias LP; Asth L; Ribeiro FM; Moreira FA
Pharmacol Biochem Behav; 2021 Jul; 206():173193. PubMed ID: 33933537
[TBL] [Abstract][Full Text] [Related]
13. Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.
Röpke J; Busanello A; Leal CQ; de Moraes Reis E; de Freitas CM; Villarinho JG; Figueira FH; Mello CF; Ferreira J; Fachinetto R
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():195-9. PubMed ID: 24747871
[TBL] [Abstract][Full Text] [Related]
14. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
Naidu PS; Kulkarni SK
Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
[TBL] [Abstract][Full Text] [Related]
15. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
Singh A; Naidu PS; Kulkarni SK
Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2009 Jan; 91(3):423-9. PubMed ID: 18789960
[TBL] [Abstract][Full Text] [Related]
17. PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice.
Sonego AB; Prado DDS; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110367. PubMed ID: 34048863
[TBL] [Abstract][Full Text] [Related]
18. Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
Hyde TM; Egan MF; Wing LL; Wyatt RJ; Weinberger DR; Kleinman JE
Psychopharmacology (Berl); 1995 Mar; 118(2):142-9. PubMed ID: 7617800
[TBL] [Abstract][Full Text] [Related]
19. Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation.
An HM; Tan YL; Shi J; Wang Z; Lv MH; Soares JC; Zhou D; Yang F; Zhang XY
Phytomedicine; 2016 Dec; 23(13):1653-1660. PubMed ID: 27823630
[TBL] [Abstract][Full Text] [Related]
20. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]